About Us


About Us

We Are Silk Tech BIOPHARMACEUTICALS

SilkTech Biopharmaceuticals is a clinical stage, privately-held company developing therapeutic drug products from our patented library of silk-derived protein (SDP) molecules. The company's lead drug product candidate is the SDP-4 eye drop which is in development for use in treating the signs and symptoms of Dry Eye Disease (DED). The SDP-4 drug candidate is designed to reduce DED-related inflammation, while simultaneously enhancing the wetting and spreading capabilities of the eye drop formulation.
Board Members

Executive Chairman

Brian Levy, OD, MSc

Dr. Levy brings more than three decades of ophthalmic industry expertise in the development of ophthalmic therapeutics. He is currently the CEO of OcuNexus Therapeutics, a clinical stage ophthalmic biopharmaceutical company. Previously, he was the Chief Medical Officer (CMO) at Aerie Pharmaceuticals and a member of the executive management team that managed the company’s successful IPO. Prior to that he served as Sr VP of R&D and CMO for Bausch + Lomb. Dr. Levy has successfully led multiple drug and device approvals in the Ophthalmic sector in both the US and Internationally, including Europe and Asia. Dr. Levy earned a Doctor of Optometry degree from the University of California, Berkeley and a Master of Science degree in Comparative Anatomy and Physiology of the Eye at the University of Waterloo.

CEO

Brian Lawrence, PhD

Dr. Lawrence is a co-founder of the company and co-inventor of the company’s functional technology. He has over 12 years’ experience in developing silk-based materials for use in a variety of medical and commercial product applications. Previously he was the CEO of Seryx Biomedical, and has prior experience working in the biotechnology and chemical manufacturing sector as a process engineering specialist. Dr. Lawrence is a recognized leader in the silk material development space, and has numerous publications and issued patents related to silk-based technologies. He earned his PhD in Biomedical Engineering from Cornell University.

Alex Soltani, BA

Mr. Soltani Founded Skyview Capital in 2005 and is Chairman of the firm’s executive and investment committees. He is a serial entrepreneur. Prior to founding Skyview Capital, Mr. Soltani worked at Platinum Equity and operated All Digital Communications. Skyview Capital has completed over 30 transactions in the technology, software, and healthcare sectors. Mr. Soltani is very involved with the operations of the portfolio companies, and works to leverage his experience to help enable rapid scaling of operations to meet both development and financial targets. Mr. Soltani holds a BA from UCLA.

Bill Mower, JD

In addition to his role as General Counsel for SilkTech, Mr. Mower is a Senior Partner at the Maslon law firm within the Business & Securities Group and also serves on their Board of Governors. He represents a wide variety of clients in connection with venture startup, financing, and M&A activities. Mr. Mower also counsels public companies in connection with their securities law compliance, general corporate matters, and represents issuers and underwriters in connection with public and private securities offerings and follow-on offerings. He also assists clients with their licensing and joint venture relationships, and serves as de-facto general counsel to numerous public and private companies. Mr Mower earned a BSBA in accounting from Drake University and a JD from the University of Minnesota.

Emmett Cunningham, Jr, MD, PhD, MPH

Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications. Dr. Cunningham is a Senior Managing Director at Blackstone Life Sciences, and is an Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine and a Research Associate at The Francis I. Proctor Foundation, UCSF School of Medicine. Previously, he was a Managing Director at Clarus Ventures, the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc., and Early Clinical Leader at Pfizer. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University, and a PhD in neuroscience from the University of California at San Diego.

CFO

Christopher Aye, MBA, CPA

Mr. Aye serves as Head of Mergers & Acquisitions for Skyview Capital. Previously, Mr. Aye served in various positions at Amgen working on multi-billion-dollar M&A integrations. Prior to Amgen, Mr. Aye served as a M&A Senior Analyst at Homestore.com, and also a Senior Associate CPA at Arthur Anderson advising start-up and emerging middle market technology companies through strategic M&A and IPO transactions. He received a BA from the University of California, Santa Barbara, in Business Economics, and his MBA from the University of Southern California.

Paul M. Karpecki, OD, FAAO

Dr. Karpecki is the Director of Corneal Services at the Advanced OSD Clinic at the Kentucky Eye Institute. He has over two decades of experience in running Dry Eye clinical trials, and has written over 1,000 publications. He has been appointed leadership roles to numerous Dry Eye related organizations, including the National Eye Institute’s Dry Eye Committee, and serves as the Chief Clinical Editor for Review of Optometry. He received his OD degree from Indiana University, and completed a fellowship in Medical Cornea and Refractive Surgery in Kansas City.

Management Team


CEO

Brian Lawrence, PhD

Dr. Lawrence is a co-founder of the company and co-inventor of the company’s functional technology. He has over 12 years’ experience in developing silk-based materials for use in a variety of medical and commercial product applications. Previously he was the CEO of Seryx Biomedical, and has prior experience working in the biotechnology and chemical manufacturing sector as a process engineering specialist. Dr. Lawrence is a recognized leader in the silk material development space, and has numerous publications and issued patents related to silk-based technologies. He earned his PhD in Biomedical Engineering from Cornell University.

VP, Research and Development

David Infanger, PhD

Dr. Infanger has over 15 years of experience in research and development, and is co-inventor of the company’s functional technology. Prior to joining the company he previously served as Technical Director in silk biomaterial development at Seryx Biomedical, and worked in biotechnology research and development at Cargill, Inc. In addition, he has multiple publications and patents surrounding silk-based biomaterials and in the field of inflammatory-based diseases. Dr. Infanger earned his PhD in Molecular Biology from the University of Iowa and continued with post-doctoral research in Biomedical Engineering at Cornell University.

Director, Clinical Operations

Jamie Christensen, BS

Ms. Christensen has over 15 years of pharmaceutical experience in Clinical Research Development spanning Phases I through IV clinical trials with a specialized focus in the field of ophthalmology. Prior to joining the company she served as the lead clinical and project team manager at multiple clinical research organizations. She was responsible for several high-profile clinical trial programs, where she specialized in pre-approved drug products. She graduated from the University of North Carolina at Chapel Hill with a BS in Biology.

CEO

Brian Lawrence, PhD

Dr. Lawrence is a co-founder of the company and co-inventor of the company’s functional technology. He has over 12 years’ experience in developing silk-based materials for use in a variety of medical and commercial product applications. Previously he was the CEO of Seryx Biomedical, and has prior experience working in the biotechnology and chemical manufacturing sector as a process engineering specialist. Dr. Lawrence is a recognized leader in the silk material development space, and has numerous publications and issued patents related to silk-based technologies. He earned his PhD in Biomedical Engineering from Cornell University.

VP, Research and Development

David Infanger, PhD

Dr. Infanger has over 15 years of experience in research and development, and is co-inventor of the company’s functional technology. Prior to joining the company he previously served as Technical Director in silk biomaterial development at Seryx Biomedical, and worked in biotechnology research and development at Cargill, Inc. In addition, he has multiple publications and patents surrounding silk-based biomaterials and in the field of inflammatory-based diseases. Dr. Infanger earned his PhD in Molecular Biology from the University of Iowa and continued with post-doctoral research in Biomedical Engineering at Cornell University.

Director, Clinical Operations

Jamie Christensen, BS

Ms. Christensen has over 15 years of pharmaceutical experience in Clinical Research Development spanning Phases I through IV clinical trials with a specialized focus in the field of ophthalmology. Prior to joining the company she served as the lead clinical and project team manager at multiple clinical research organizations. She was responsible for several high-profile clinical trial programs, where she specialized in pre-approved drug products. She graduated from the University of North Carolina at Chapel Hill with a BS in Biology.

Medical Advisory Board


Founding Partner of Minnesota Eye Consultants

Richard L. Lindstrom, MD

Dr. Lindstrom is the founder and attending surgeon at Minnesota Eye Consultants, and has over 40 years of ophthalmology industry related experience as well as extensive experience serving as a board director and medical advisor from startups to large corporations. He has been at the forefront of ophthalmology’s evolutionary changes throughout his career, has been awarded numerous professional honors, holds over 40 issued patents in ophthalmology, and has been involved in the development of numerous drugs and medical devices that are used in clinical practices globally. Dr. Lindstrom holds a B.A. in Pre-Medical Studies, a B.S. in Medicine and an M.D. from the University of Minnesota.

Director of Cornea Services at Cincinnati Eye Institute

Edward Holland, MD

Dr. Edward Holland is the Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati. He has a national and international reputation for his knowledge and expertise in the field of cornea and external disease. Dr. Holland is the author of over 250 articles in peer review journals, has co-edited 4 editions of Cornea, and serves on numerous boards as a director and medical advisor for both startups and large corporations. He attended the Loyola-Medical School in Chicago and trained in Ophthalmology at the University of Minnesota. He completed a fellowship in cornea and external disease at the University of Iowa, and then a second fellowship in ocular immunology at the National Eye Institute.

Ophthalmic Industry Consultant

Tim Comstock, OD, MS, FAAO

Dr. Comstock is a recognized industry consultant in ophthalmology for advising in clinical trial design and development. For 25 years Dr. Comstock lead the clinical development and medical science departments of Bausch & Lomb, Inc. (Rochester, NY). During that time Dr. Comstock had clinical responsibility for several new ophthalmic drug and device approvals both in the US and globally. He has published scientific papers on topics ranging from studies in dry eye to implanted ophthalmic devices. Dr. Comstock received his Doctor of Optometry and his Master of Science degrees from The Ohio State University.

VP, Scientific Affairs and Real-World Evidence at Evidera of PPD, LLC

Debra Schaumberg, ScD, OD, MPH 

Dr. Schaumberg is an internationally recognized expert in ophthalmology clinical development, medical affairs, and epidemiology. She brings over 20 years of experience designing and leading early through late phase randomized trials and all aspects of real-world evidence generation and integration, including pivotal work in DED. She brings diverse experience from academia, biotherapeutic start-ups, venture capital teams, and biopharma, and has authored hundreds of scientific publications, lectures, and scientific presentations. She is currently Vice President, Scientific Affairs at Evidera-PPD, with adjunct positions at the Harvard TH Chan School of Public Health and the University of Utah School of Medicine. Debra received her ScD from the Harvard TH Chan School of Public Health, an MPH from the Johns Hopkins Bloomberg School of Hygiene and Public Health, and an OD from the Illinois College of Optometry.

President & CEO of PharmaLogic Development

Gary D. Novack, PhD

Dr. Novack provides regulatory affairs oversight for the company, and is a board-certified clinical pharmacologist specializing in ophthalmology. He has over 40 years of pharmaceutical industry experience, and has provided critical roles in the development and approval of over 50 products. He has authored nearly 300 publications and serves on several editorial boards for ophthalmic journals. Dr. Novack is also a Clinical Professor of Ophthalmology at the University of California, Davis School of Medicine, Chaired the 2017 Clinical Trials and Regulatory sub-committee of the Dry Eye Workshop II, and was a Regent of the University of California. He earned his PhD in Pharmacology and Environmental Toxicology from the University of California, Davis and completed a post-doctoral fellowship in Neurophysiology at the University of California, Los Angeles.

Founding Partner of Ophthalmic Consultants of Connecticut

Dr. Eric Donnenfeld

Dr. Eric D. Donnenfeld is a founding partner of Ophthalmic Consultants of Connecticut. He is the Surgical Director of the Lions Eye Bank for Long Island, and is president elect of the International Intraocular Implant Society. He is the editor-in-chief of EyeWorld, and has written over 190 peer-reviewed papers and 38 book chapters in clinical ophthalmology. He is a prestigious Fellow of the American Academy of Ophthalmology and has received several honors including both the Lifetime Achievement and Secretariat Award. He graduated from Dartmouth College and attended Dartmouth Medical School. He was Chief Resident at Manhattan Eye, Ear and Throat Hospital, and then completed a Cornea Fellowship at Wills Eye Hospital. He is a trustee of Dartmouth Medical School and a Clinical Professor of Ophthalmology at NYU.